MENLO PARK, Calif.–(BUSINESS WIRE)–AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.On October 19, 2026, the Compensation Committee granted inducement equity awards to two newly hired employees consisting in the aggregate of options to purchase 10,565 shares of the Company’s common stock and 5,2

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.